


PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : C12P 1/00, A61K 9/52 C12N 5/00	A1	(11) International Publication Number: WO 93/00439 (43) International Publication Date: 7 January 1993 (07.01.93)
(21) International Application Number: PCT/US92/05390 (22) International Filing Date: 25 June 1992 (25.06.92) (30) Priority data: 722,894 28 June 1991 (28.06.91) US (71) Applicant: BROWN UNIVERSITY RESEARCH FOUNDATION [US/US]; 42 Charlesfield Street, Providence, RI 02912 (US). (72) Inventors: AEBISCHER, Patrick ; 7 Cheshire Drive, Barrington, RI 02806 (US). WINN, Shelley, R. ; 9 Hall Road, Providence, RI 02904 (US). (74) Agents: ENGELLENNER, Thomas, J. et al.; Lahive & Cockfield, 60 State Street, Boston, MA 02109 (US).		(81) Designated States: AU, CA, FI, JP, KR, NO, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, MC, NL, SE). Published <i>With international search report.</i>

(54) Title: IN VIVO DELIVERY OF ACTIVE FACTORS BY CO-CULTURED CELL IMPLANTS**(57) Abstract**

Methods and devices are disclosed for the delivery of an active factor from an implanted co-culture of an active factor-secreting cell obtained from a first source and an augmentary substance-secreting cell obtained from a second source different from the first source, to a target region in a subject. The co-culture is maintained within a biocompatible, semipermeable membrane in which the augmentary substance secreted by the augmentary substance-producing cells stimulates the active factor-producing cells to secrete active factor. The semipermeable membrane permits the diffusion of the active factor therethrough while excluding detrimental agents present in the external environment from gaining access to the co-culture.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FI	Finland	MI	Mali
AU	Australia	FR	France	MN	Mongolia
BB	Barbados	GA	Gabon	MR	Mauritania
BE	Belgium	GB	United Kingdom	MW	Malawi
BF	Burkina Faso	GN	Guinea	NL	Netherlands
BG	Bulgaria	GR	Greece	NO	Norway
BJ	Benin	HU	Hungary	PL	Poland
BR	Brazil	IE	Ireland	RO	Romania
CA	Canada	IT	Italy	RU	Russian Federation
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland	KR	Republic of Korea	SN	Senegal
CI	Côte d'Ivoire	LI	Liechtenstein	SU	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TC	Togo
DE	Germany	MC	Monaco	US	United States of America
DK	Denmark	MG	Madagascar		
ES	Spain				

WO 93/00439

PCT/US92/05390

- 4 -

IN VIVO DELIVERY OF ACTIVE FACTORS
BY CO-CULTURED CELL IMPLANTS

5 Background of the Invention

The technical field of this invention is the treatment of active factor deficiency disorders and, in particular, the treatment of diseases and
10 disorders which may be remedied by treatment with active factors, such as neurotransmitters, neuromodulators, hormones, trophic factors, cofactors, and growth factors. All these substances are characterized by the fact they are secreted by
15 "source" cells and produce a specific change in a "target" cell or in the source cell itself.

Deficits in active factors have been implicated in disease with very different
20 phenotypes. For example, lack of neurotransmitter-mediated synaptic contact causes neuropathological symptoms, and can also lead to the ultimate destruction of the neurons involved.

WO 93/00439

PCT/US92/05390

-2-

More particularly, paralysis agitans, commonly known as Parkinson's disease, is characterized by a lack of the neurotransmitter, dopamine, within the striatum of the brain, secondary
5 to the destruction of the dopamine secreting cells of the substantia nigra. Affected subjects demonstrate a stooped posture, stiffness and slowness of movement, and rhythmic tremor of limbs, with dementia being often encountered in very advanced stages of
10 the disease.

The direct administration of purified or synthetic dopamine, its precursors, analogs and inhibitors has been studied for therapeutic value in
15 the treatment of Parkinson's disease. These studies have revealed various problems with delivery, stability, dosage, and cytotoxicity of the applied compounds. To date, none of these approaches has demonstrated more than marginal therapeutic value.
20 Brain derived growth factor also may have potential value in the treatment of Parkinson's disease since it has been demonstrated to maintain the viability of striatal neurons in vitro.

25 Many other deficiency diseases, such as diabetes, myxedema, growth deficiencies and perhaps even Alzheimer's disease, appear to be based in whole or in part on the absence or limited availability of a critical active factor to target cells.

30

In an attempt to provide a constitutive supply of drugs or other factors to the brain or other organs or tissues at a controlled rate, miniature osmotic pumps have been used. However,

WO 93/00439

PCT/US92/05390

-3-

limited solubility and stability of certain drugs, as well as reservoir limitations, have restricted the usefulness of this technology. For example, controlled sustained release of dopamine has been attempted by implanting dopamine encapsulated within bioresorbable microcapsules (McRae-Degueurce et al. (1988) Neurosci. Lett. 92:303-309). However, controlled sustained release of a drug from a bioresorbable polymer may rely, e.g., on bulk or surface erosion, which may be due to various hydrolytic events. Erosion often relies on hydrolytic events which increase the likelihood of drug degradation, and complicates establishment of predictable release rates. Other disadvantages associated with pumps and resorbable polymers include finite loading capabilities and the lack of feedback regulation.

The implantation of cells capable of constitutively producing and secreting biologically active factors has also been attempted. Recently, remedial transplantation of neurotransmitter-secreting tissue has been accomplished using the patient's own tissue so as not to elicit an immune response. For example, catecholamine-secreting tissue from the adrenal medulla of patients suffering from Parkinson's disease has been implanted in their striatum with some success. However, this procedure is only used in patients less than 60 years of age, as the adrenal gland of older patients may not contain sufficient dopamine-secreting cells. This restriction limits the usefulness of the procedure as a remedy since the disease most often affects older people.

WO 93/00439

PCT/US92/05390

-4-

Other approaches have been attempted to transplant cells into brain tissue even though the brain is considered "immuno-privileged", rejection ultimately occurs with both allografts and
5 xenografts. This problem necessitates the co-administration of immuno-suppressors, the use of which renders their own set of complications and deleterious side-effects.

10 A number of researchers have proposed the use of microcapsules, i.e., tiny spheres which encapsulate a microscopic droplet of a cell solution, for both therapeutic implantation purposes and large scale production of biological products.

15 An alternative approach has been macroencapsulation, which typically involves loading cells into hollow fibers and then sealing the extremities. In contrast to microcapsules,
20 macrocapsules offer the advantage of easy retrievability, an important feature in therapeutic implants.

However, there are shortcomings in both the
25 microcapsule and macrocapsule approaches to cell culturing. The viability of encapsulated cells as in vivo implants often fails for as yet undetermined reasons. Even when the cells remain viable, they sometimes secrete their products at lower than
30 therapeutically useful levels.

WO 93/00439

PCT/US92/05390

-5-

Therefore, there exists a need for improved therapies for the treatment of active factor deficiency disorders in general and, in particular, a need for therapy devices which can revitalize or
5 replace the functions of dysfunctional areas of the brain or other organs without causing excessive trauma. More specifically, there exists a need for methods of enhancing and/or sustaining the delivery of biologically active factor to a localized region
10 of a subject.

Accordingly, it is an object of the present invention to provide more reliable or more potent, implantable, therapy devices useful for the sustained
15 and controlled delivery of a biologically active factor to a subject, and more particularly, to provide devices which can deliver a biologically active factor, e.g., a neuroactive trophic factor, or growth factor, to a localized region of a tissue or
20 organ in a subject.

WO 93/00439

PCT/US92/05390

-6-

Summary of the Invention

Methods and devices are disclosed herein for the constitutive and controlled delivery of at least one biologically active factor to an organ or tissue of a subject suffering from a deficiency or organ dysfunction. This active factor is provided by a synergistic combination of at least two cell types derived from different populations of cells from separate sources.

In accordance with the method of present invention, a co-culture of at least one active factor-secreting cell obtained from a first source and at least one augmentary substance-producing cell obtained from a second source different from the first source, are encapsulated within a selectively permeable membrane. This membrane protects the co-culture from autoimmune and viral assault while allowing essential nutrients, cellular waste products, and secreted active factor to diffuse therethrough to the local external environment or to the co-culture.

As used herein, "deficient" or "deficiency" refers to the state of an organ or tissue which can be therapeutically altered by the presence of an active factor-producing cell.

"Active factor-producing cell" as used herein refers to any cell which produces and secretes an active factor such as a neurotransmitter, neuromodulator, or catecholamine, growth factor, cofactor, trophic factor, or hormone. These include

WO 93/00439

PCT/US92/05390

-7-

cells that produce insulin, Factor VIII, trophic factors such as erythropoietin and growth hormones, biological response modifiers such as lymphokines and cytokines, enzymes, and antibodies from

5 antibody-secreting cells, neurotransmitters, such as enkephalins, dynorphins, Substance P, and endorphins, GABA, glutamic acid, serotonin, dopamine norepinephrine, epinephrine, and acetylcholine, as well as growth factors such as NGF, EGF, PDGF, and an

10 array of fibroblast growth factors, and neurotrophic factors such as BDNF and NT-3. This term also includes any cell which produces and secretes analogs, agonists, derivatives, or fragments of an active factor having the biological activity of the

15 active factor as well as inhibitors of normal biological factors in some instances where disease is caused by an excess of such biological factor (e.g., as in Huntington's Disease). In addition, cells which naturally produce and secrete active factor, as

20 well as those which are genetically engineered to produce active factor, are included.

"Augmentary substance" as used herein includes any molecule produced by an augmentary

25 substance-producing cell which induces another type of cell to produce and secrete active factor and/or enhances the production of active factor, generally. This term also encompasses those molecules which cause cells to grow, proliferate, and/or

30 differentiate into active factor-producing cells. Preferred augmentary substances include growth factors such as nerve growth factor (NGF), fibroblast growth factor (FGF), epidermal growth factor (EGF), platelet derived growth factor (PDGF), trophic

factors such as brain-derived neurotropic factor (BDNF), and neurotrophin-3 (NT-3), cytokines, lymphokines, and hormones. Other preferred augmentary substances of the invention includes
5 effectors of various membrane receptors such as glutamate or nicotine. The term "augmentary substance" also encompasses not only factors but also agonists, analogs, derivatives, and fragments of an augmentary substance which have the ability to induce
10 cells to secrete active factor and/or stimulates such cells to produce active factors including, for example, recombinantly produced analogs of FGF, EGF, PDGF, NT-3, BDNF, and NGF.

15 The term "augmentary substance-producing cell" refers to a cell obtained from one source which produces and secretes into the local environment a molecule which induces a different cell obtained from a separate source to synthesize and secrete active
20 factor. In one embodiment of the invention, the augmentary substance-producing cell is one which normally secretes that augmentary substance, such as NGF-producing hippocampal cells or PDGF-producing platelets. In another embodiment, the augmentary
25 substance-producing cell has been genetically engineered to express and secrete that factor (such as the NFG-secreting rat1 N.8-21 fibroblast cell line).

30 The augmentary substance-producing cell and the active factor-producing cell are different types of cells and are isolated from separate sources.

WO 93/00439

-9-

PCT/US92/05390

In one embodiment of the invention, the active factor is a neurotransmitter, and the augmentary substance is a neurotransmitter-stimulating factor. For example in one preferred 5 embodiment, the neurotransmitter-secreting cell is one which secretes dopamine such as cells isolated from the adrenal medulla, embryonic ventral mesencephalic tissue, or are neuroblastic cells. In alternative embodiments, the encapsulated cells 10 produce other neurotransmitters such as gamma aminobutyric acid, serotonin, acetylcholine, norepinephrine, epinephrine, glutamic acid, endorphins, enkephalins, dynorphin, or other compounds necessary for normal nerve functions. In 15 this embodiment the augmentary substance-secreting cells are those which secrete NGF, EGF, BDGF, NT-3, PDGF, or the like.

Alternatively, the encapsulated cells of the 20 present invention may secrete an agonist, analog, derivative, or fragment of an active factor or augmentary substance which is biologically active. For example, an embodiment of the invention includes cells which secrete bromocriptine, a dopamine 25 agonist, or cells which secrete L-dopa, a dopamine precursor.

The encapsulated cells of the present invention may be allospecific, or cells obtained from 30 matched tissue of another of the same species. Alternatively, the cells may be xenospecific, or cells obtained from a similar tissue of a different species. However, regardless of their source, the cells to be transplanted form a co-culture consisting

WO 93/00439

PCT/US92/05390

-10-

of a cell obtained from one source which synthesizes and secretes a desired active factor in which the region or tissue of a subject is deficient, and a second cell obtained from a second source (different
5 than the first source) which synthesizes and secretes augmentary substance.

In one embodiment, the region targeted for implantation of active factor-secreting cells is the
10 brain or other CNS region in the subject, since this is often the site of many neurological deficiencies or disorders. In other embodiments the targeted area may be the liver, pancreas, kidney, or bone marrow, for example.

15

The terms "selectively permeable" and "semipermeable" are used herein to describe biocompatible membranes which typically allow the diffusion therethrough of solutes having a molecular
20 weight of up to about 150,000 daltons. The preferred semipermeable membrane materials include polymeric materials selected from the group consisting of acrylic copolymers, polyvinylidene fluoride, polyurethane, polyvinylchloride, polyurethane
25 isocyanates, polyalginate, cellulose acetate, cellulose nitrate, polysulfone, polyvinyl alcohols, polystyrene, polyamide, polymethyl-acrylate, polyacrylonitrile, polyethylene oxide, and/or derivatives, or mixtures thereof.

30

In one aspect of the invention an encapsulated co-culture of active factor-producing cells and augmentary substance-secreting cells is implanted within a subject and then retrieved when

WO 93/00439

PCT/US92/05390

-11-

the cells have expired, are no longer functional, or are no longer required to correct the deficiency disorder. Retrieval can be accomplished by means of a biocompatible, nonresorbable guide wire which is
5 attached to the encapsulating membrane.

In another aspect of the present invention, the encapsulating membrane is in the shape of a tube, with its openings being covered by removable plugs or
10 caps. Such a construct enables the easy replacement of either type of cell within the membrane with other like cells by way of the uncovered tube openings after retrieval from the subject via the attached guide wire.

15

Alternatively, the membrane is in the form of a macrocapsule or microcapsule. These capsules may include an integral tether that extends from the capsule. The tether preferably is of a length
20 sufficient to reach at least from the treatment site to the proximity of the insertion site. The tether may also be a part of the cell capsule itself that extends above the insertion site. Once the vehicle capsule is positioned in the passageway to the
25 treatment site, the tether may then be secured at the insertion site, e.g., by securing the tether to the outer surface of the skull or other bone and its other end proximal to the insertion site by means of surgical staples, biocompatible adhesive, or other
30 methods available and known to those skilled in the art. Following positioning of the capsule at the treatment site, the insertion site may be closed or capped to prevent introduction of extraneous material to the passageway and the treatment site.

WO 93/00439

PCT/US92/05390

-12-

In another aspect of the invention, the encapsulated, co-cultured cells can be used to produce active factors in vitro, e.g. in a physiologically compatible aqueous medium. The active factor can be harvested by removing at least a portion of the medium and isolating the active factor which has been secreted into it by the encapsulated cells. Alternatively, the semipermeable membrane can be designed to retain the active factor, and the active factor would then be harvested by separating the encapsulated cells from the medium, and lysing the capsules to extract the active factor in concentrated form.

15 The invention will next be described in connection with certain illustrated embodiments. However, it should be clear that various modifications, additions, and subtractions can be made without departing from the spirit or scope of the invention. For example, the present invention should not be read to require, or be limited to, particular cell lines or a particle membrane shape or material described by way of example or illustration.

WO 93/00439

PCT/US92/05390

-13-

Brief Description of the Drawings

The invention itself can be more fully understood from the following description when read 5 together with the accompanying drawings in which:

FIG. 1 is a schematic illustration of an implantable co-culture device for delivering active factor, according to one aspect of the present 10 invention;

FIG. 2 is a schematic illustration of an implantable and retrievable co-culture device for delivering active factor, according to a second 15 aspect of the invention;

FIG. 3 is a schematic illustration of an implantable, retrievable, and rechargeable co-culture device for delivering active factor, according to 20 another aspect of the invention;

FIG. 4 is a schematic illustration of an implantable co-culture device for delivery of active factor according to yet another aspect of the 25 invention;

FIG. 5 is a schematic illustration of an implantable, co-culture device including a gel sphere according to another aspect of the invention; 30

FIG. 6 is a schematic illustration of an implantable, co-culture device including a coated gel sphere according to yet another aspect of the invention;

WO 93/00439

PCT/US92/05390

-14-

FIG. 7 is a schematic illustration of an implantable co-culture device including a macrocapsule according to another aspect of the invention;

5

FIG. 8 is a schematic illustration of an implantable co-culture device including several cell compartments according to another aspect of the invention;

10

FIG. 9 is a schematic illustration of an implantable, co-culture device comprising a split-wall capsule having two communicating cell compartments according to another embodiment of the invention;

FIG. 10 is a graphic representation of the average potassium-evoked release of neurotransmitters from approximately 200 medium density chromaffin-loaded microcapsules/well after 1, 4, and 8 weeks of maintenance in vitro; and

FIG. 11 is a graphic representation of the average potassium-evoked release of neurotransmitters from approximately 300 co-seeded microcapsules/well containing chromaffin and NGF-producing fibroblasts after 1, 4, and 8 weeks of maintenance in vitro.

WO 93/00439

PCT/US92/05390

-15-

Detailed Description of the Invention

A method for the constitutive delivery of active factor to a localized target region of a subject suffering from an active factor-curable deficiency or dysfunction, and a device for practicing this method, have been devised. The method includes providing active factor-producing cells obtained from a first source and providing augmentary substance-secreting cells obtained from a second source different from the first source. These cells are most often of two different cell types. The cells are then encapsulated within a protective, selectively permeable membrane or cell culture device, which can be implanted into a target region of a subject or cultured in vitro. The co-culturing of these two distinct cell types has a synergistic effect on the expression and secretion of active factor by the active factor-producing cell.

The target region may be any part of the subject's anatomy which responds to, and for which increased levels of active factor have therapeutic valid function. This region may be an organ, tissue or any part of a functional body system, such as the nervous system. Nervous system implants will often be within the brain, as it is the source of numerous neurological dysfunctions.

WO 93/00439

PCT/US92/05390

-16-

These encapsulated co-cultures may be allospecific, or cells from another of the same species as the subject in which they are to be implanted, or they may be xenospecific, or those from another of a different species. More particularly, they may be derived from a body organ which normally secretes a particular active factor or an augmentary substance in vivo.

For example, useful neurotransmitter-producing cells include those dopamine-secreting cells isolated from the embryonic ventral mesencephalon, neuroblastoid cell lines, or the adrenal medulla. In addition, adrenal chromaffin cells, when isolated from the cortical cells that secrete glucocorticoids, may differentiate into a neuronal phenotype. Extensive neuritic outgrowths from the isolated chromaffin cells is dependent on the presence of NGF and/or other growth factors when maintained in culture. These growth factors may be provided by growth factor-producing cells such as hippocampal cells, platelets, brain tissue and endocrine gland tissue.

In addition, any cell which secretes a processable precursor, analog, derivative, agonist, or fragment having the biological activity of a desired active factor are useful. Such cells include, for example, cells which elicit bromocriptine, L-dopa, preproinsulin, and the like.

WO 93/00439

PCT/US92/05390

-17-

Further, any cells which have been genetically engineered to express active factor or augmentary substance, or agonists, precursors, derivatives, analogs, or fragments thereof which have similar active factor or augmentary substance activity, are also useful in practicing this invention (see, e.g., Rosenberg et al. (1988) Science 242:1575-1578). Thus, in such an approach, the gene which encodes the augmentary substance or active factor, or the analog or precursor thereof, is either isolated from a native cell line or constructed by DNA manipulation. The gene can then be incorporated into a plasmid, which in turn is transfected into a host cell for expression. The cells which express the active factor or augmentary substance can be grown in vitro until a suitable density is achieved. A portion of the culture is then used to seed the implantable device. See, e.g., Sambrook et al., Molecular Cloning. A Laboratory Manual, Cold Spring Harbor Laboratory (1989), herein incorporated by reference for further discussion of cloning vehicles and gene manipulation procedures. Examples of such genetically engineered cell lines include dopamine-producing PC12 cells and NGF-producing rat N.8-21 fibroblasts.

Cells obtained from tissue sample may be homogeneous, i.e., of the same cell type. Isolation of a homogenous population of cells may be accomplished by separating the cells of the tissue sampled (e.g., by enzymatically digesting

intercellular adhesions), and then sorting them on the basis of morphology and/or biological activity. Cells isolated from a homogeneous population of cells in tissue culture need only be cleanly separated from
5 their neighbors and from cellular debris.

Regardless of the source, the augmentary substance-producing cells and the active factor-secreting cells are placed into an
10 implantable, selectively permeable membrane which protects the resulting co-culture from deleterious encounters with viruses and elements of the immune system or other culture environment. Such protection is particularly important for preserving allografts
15 or xenografts which are eventually considered foreign even in the "immuno-privileged" regions of the body such as the brain. Accordingly, the membrane bars viruses, macrophages, complement, lymphocytes, and, in some embodiments, antibodies from entry while
20 allowing the passage of nutrients, gases, metabolic breakdown products, other solutes, and the neurotransmitter to pass therethrough. Any biocompatible and nonresorbable materials having pores enabling the diffusion of molecules having a
25 molecular weight of up to about 150 kD are useful for practicing the present invention, with acrylic copolymers, polyvinylchloride, polystyrene, polyurethane, polyamide, polymethacrylate, polysulfane, polyacrylate, polyvinylidene fluoride,
30 polyurethane, isocyanate, polyalginate, cellulose acetate, polysulfone, polyvinyl alcohols, polyacrylonitrile, polyethylene oxide, and derivatives, and mixtures thereof being the most preferable.

WO 93/00439

PCT/US92/05390

-19-

The cell culture device may take any shape which will accommodate the two types of cells to be encapsulated, and which will not cause undue trauma upon surgical implantation. Useful shapes include a variety of macrocapsules, microcapsules, multicapsules, and multicompartment capsules with split walls.

One preferable implantable co-culture device 10 shown in FIG. 1 is a tubular, selectively permeable membrane 22 having ends 12 and 14 through which active factor-secreting cells 25 and augmentary substance-producing cells 27 are loaded into cell compartment 16. Ends 12 and 14 may then be permanently occluded with caps 17 and 19 or, alternatively, with an epoxy glue or sutures of a biocompatible and nonresorbable material like polypropylene. The device 20 can be surgically implanted into a region of the subject's body such that membrane 22 is in immediate contact with internal tissues or fluids tissues.

The method of the present invention may include an additional step whereby the initially encapsulated and implanted cells are removed from the subject in the event that they cease to produce active factor or augmentary substance, expire, or are no longer needed to correct the neurological dysfunction. As illustrated in FIG. 2, retrieval of implanted co-culture device 20 is preferably accomplished by means of guide wire 18 which is permanently attached to end cap 17 or 19. This wire may be constructed of any nonresorbable, biocompatible material with enough tensile strength to support the cell culture device.

WO 93/00439

PCT/US92/05390

-20-

The cellular contents of the device may be replaced in the event that it is desirable to reimplant the device after its retrieval. A exemplary cell culture device 30 useful in practicing
5 this method is shown in FIG. 3. Device 30 is tubular, having ends 12 and 14 reversibly covered with removable, friction-fitted caps 22 and 24, respectively, to enable the extraction and replacement of cells 25 and 27 in cell compartment 16
10 with new cells. The device 30 can be surgically implanted into the brain of a subject such that guide wire 18 is located directly under the epithelial tissues of the head, and membrane 22 is in immediate contact with brain tissue.

15

Another embodiment of the invention is shown in FIG. 4. The cell culture device 40 includes capsule 42 filled with at least one augmentary substance-producing cell 26 and at least one active
20 factor-secreting cell 27. In a preferred embodiment, the macrocapsule 42 includes a tether 44 or rod extending from and integral with the capsule. The vehicle further includes a permeable, semi-permeable, or permselective membrane 18 surrounding the
25 macrocapsule 42. The tether 44 is generally constructed from an impermeable membrane material or may be coated with a material which makes the tether impermeable. In one embodiment, the impermeable protective barrier material may coat a portion of the
30 outer membrane of the capsule. Exemplary protective barrier material includes polyethylene oxides,

WO 93/00439

PCT/US92/05390

-21-

polypropylene oxides, silicon, hydrogels, and derivatives and mixtures thereof. It should be appreciated that the semipermeable membrane may have alternative shapes that will accommodate the cells 5 such as, for example, a hollow rod, sack, or multiple fibers.

The outer membrane may be a polymer material and may include a surfactant, an anti-inflammatory 10 agent, angiogenic factors, and/or an anti-oxidant. The specific type of polymer, surfactant, or other additive will depend on the material to be encapsulated and the configuration of the extrusion apparatus. Exemplary anti-inflammatory agents 15 include corticoids such as cortisone and ACTH, dexamethasone, cortisol, interleukin-1 (IL-1), and its receptor antagonists, and antibodies to TGF- β , to IL-1, and to interferon-gamma. Exemplary surfactants include Triton-X 100 (Sigma Chemicals) and Pluronics 20 P65, P32, and P18. Exemplary anti-oxidants include vitamin C (ascorbic acid) and vitamin E.

In the event that the supply of active factor or augmentary substance is spent, (e.g., cells 25 responsible for secreting such factors have expired or are no longer productive, or are no longer needed to correct the particular dysfunction), vehicle 40 can be removed and replaced. Retrieval of implanted vehicle 40 can be accomplished by pulling it out of 30 the treatment site by its tether 44. One way to effect removal is to use a pair of forceps after exposing the tether 44 by removal of the cap 62. Cap

WO 93/00439

PCT/US92/05390

-22-

62 may be located directly under the patient's epithelial tissues. The vehicle 40 may be replaced with a new insert in the event that additional therapy is required. Likewise, cells encapsulated 5 within capsule 42 can also be retrieved by removing capsule 42.

The permeable portion (e.g., capsule 42) of vehicle 40 is implanted at or near the target 10 treatment site 12, while the impermeable portion (e.g., tether 42) confines the neuroactive factor to within the boundaries of the insert. The permeable portion includes a polymeric material having pores of a particular size (i.e., having a particular 15 molecular weight cut-off) that excludes some molecules from passage therethrough, while permitting the passage of others. In this way, the diffusion of neurotransmitter from the insert to the treatment site is allowed, while the passage of larger 20 deleterious elements such as viruses, Clq or C3b complement component, and various proteases is effectively barred. For example, vehicles with pores having a molecular weight exclusion of from about 25 kD to about 300 kD are useful, with those having 25 pores with a molecular weight cut off of from about 50 kD to about 200 kD being particularly preferred.

Other aspects of the invention are shown in FIGS. 5 and 6. In FIG. 5, hydrogel or alginate gel 30 sphere or microcapsule 50 encapsulates the co-culture therein. The gel microcapsule 60 in FIG. 6 is coated with a membrane 29 of, for example, poly-lysine or a thermoplastic material.

WO 93/00439

PCT/US92/05390

-23-

The co-culture vehicle alternately may be an extruded macrocapsule 70 shown in FIG. 7 or multimacrocapsule 80 shown in FIG. 8. In these aspects of the invention, cells 25 and 27 are 5 encapsulated within a semipermeable, polymeric membrane 31 by co-extruding an aqueous cell suspension and a polymeric solution through a common port to form a spherical or tubular extrudate having a polymeric outer coating 31 which encapsulates the 10 cell suspension.

To prepare such a vehicle, the cell suspension and the polymeric solution may be extruded through a common extrusion port having at least two 15 concentric bores such that the cell suspension is extruded through the inner bore and the polymeric solution is extruded through the outer bore. The polymeric solution coagulates to form an outer coating. As the outer coating is formed, the ends of 20 the tubular extrudate can be sealed at intervals to define a single cell compartment 16 (FIG. 7) or multiple cell compartments 16 connected by polymeric links 37 (FIG. 8).

25 In yet another embodiment of the invention shown in FIG. 9, a vehicle 90 with an internal partition wall encapsulates active factor-secreting cells 25 in a cell compartment 46 separate from cell compartment 48 in which augmentary substance- 30 producing cells 27 are encapsulated. These compartments are surrounded by a common outer membrane wall 31, but are also separated from each other by, while communicating through, semipermeable membrane 52 through which augmentary substance can 35 diffuse to stimulate active factor-producing cells 25 to secrete active factor.

WO 93/00439

PCT/US92/05390

-24-

The following non-limiting examples more fully illustrate preferred features of the invention. These examples describe the ability of a device including a co-culture of isolated chromaffin 5 cells co-seeded with an NGF-releasing cell type encapsulated within selectively permeable microsphere membranes to release the catecholamines dopamine, norepinephrine, and epinephrine. However, this invention is not limited to the cell types described 10 in these examples, nor to the type or shape of selectively permeable membrane system described. For example, extruded macrocapsule devices having one or more cell compartments are included as well as coated and uncoated microcapsules.

15

EXAMPLE 1

Cellular Preparations

Dissociated bovine adrenal chromaffin cells 20 were isolated as described by Pollard et al. (J. Biol. Chem. (1984) 259:1114-22) and Sagen et al (J. Neurocytol. (1990) 19:697-707). The cells were maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 6% fetal calf serum (FCS) 25 (Gibco, Grand Island Biological Co., Grand Island NY) at 37°C in a water-saturated, ambient air atmosphere containing 5% CO₂. Approximately one week following the isolation procedure, cells were harvested by aspiration, collecting the supernatant and 30 centrifuging at 800 x g.

WO 93/00439

PCT/US92/05390

-25-

The fibroblast cell line rat1 N.8 was genetically modified through infection with a retroviral vector containing the mouse nerve growth factor (NGF) cDNA (Short et al. (1990) Devel. 5 Neurosci. 12:34-45). The clonal line designated rat1 N.8-21 was maintained in DMEM supplemented with 10% FCS and utilized for co-seeding with bovine chromaffin cells after removal from tissue culture flasks by trypsin-EDTA treatment. The rat1 N.8-21 10 NGF releasing clonal cell line was previously assayed by in ELISA technique and the calculated release of NGF was 165 pg/10⁵ cells/hour. The NGF released by the rat1 N.8-21 clonal cell line was shown to be biologically active by its ability to induce neuritic 15 extensions in cultured PC12 cells.

EXAMPLE 2

Encapsulation Procedure

20 Chromaffin cells in 250 μ l DMEM were suspended in 800 μ l 2% (w/v) isotonic sodium alginate (KelcoGel HV, Kelco, NJ) at a density of 2, 5, and 10 x 10⁶/ml designated low, medium, and high, respectively. The co-seeding conditions consisted of 25 2 x 10⁶ cells/ml of the rat1 N.8-21 with 3 x 10⁶ cells/ml chromaffin cells mixed in 250 μ l Matrigel® (Collaborative Research, Lexington, MA) suspended in 800 μ l 2% isotonic sodium alginate. Matrigel®, a hydrogel containing laminin (7 mg/ml) and type IV 30 collagen (0.25 mg/ml), was used as a substratum for the fibroblasts. Microbeads of the cellular/alginate suspensions were formed by syringe-pump extrusion and gelled by immersion in a mixing 1.0% CaCl₂ solution in physiologic saline at pH 7.4 (5 min). The

WO 93/00439

PCT/US92/05390

-26-

cell-loaded gelled beads were washed twice with 25 ml of 0.85% NaCl buffered to pH 7.4 with 2.5mM HEPES (N-2-Hydroxyethylpiperazine-N'-2-ethanesulfonic acid, Sigma, St. Louis, MO), and then once in 0.85% NaCl/HEPES pH 8.0. A 0.05% solution of poly-L-lysine (Mw 36-38,000, Sigma) in 0.85% NaCl, pH 7.6, was added to the cell suspended beads and mixed for 6 min. Washes of 0.85% NaCl/HEPES pH 7.4 were followed by immersion in 0.15% sodium alginate for 5 min. The beads were washed in NaCl/HEPES pH 7.4, and an additional layer of poly-L-lysine and alginate was added as described above, prior to exposure of the beads to 50 mM sodium citrate for 5 min to reliquify the entrapped alginate. The microencapsulated chromaffin cells were washed twice in 0.85% NaCl/HEPES pH 7.4 and twice in conditioned culture media before being placed in the incubator.

Approximately 200 cell-loaded microcapsules per well were placed in individual wells of a 24 multiwell tissue culture plate (Falcon 3047). Catecholamine analysis was performed by ion-pair reverse phase high performance liquid chromatography at 1, 4, and 8 weeks on cell-loaded microcapsules maintained in vitro. The diameters of 20 microcapsules from each group were measured with a morphometric analysis system (CUE-2, Olympus Corp., Lake Success, NY).

WO 93/00439

PCT/US92/05390

-27-

EXAMPLE 3In Vitro Release Kinetics

Basal and potassium-evoked catecholamine
5 (neurotransmitter) release profiles under static
conditions were determined by high performance liquid
chromatography (HPLC) with an electrochemical
detector (LCEC). Both basal (5.4 mM K⁺) and
potassium-evoked (56 mM K⁺) release was measured by
10 analyzing 450 µl 0.29 mM ascorbated HBSS incubations
for 15 min each pretreated with 50 µl of 1.1 N HClO₄
prior to column injection. The medium density
chromaffin cell-loaded microcapsules and the
co-seeded microcapsules were also challenged with 1
15 mM d-amphetamine sulphate in HBSS under the same
conditions after being maintained for 4 and 8 weeks
in vitro. The same wells from each group were
repeatedly stimulated over time. The HPLC system
consisted of a Rabbit™HPX solvent-delivery system
20 (Rainin Instrument Co. Inc., Woburn, MA),
reverse-phase-HR-80-column, and a Coulochem
multi-electrode electrochemical detector (ESA,
Bedford, MA) operated at 1.4 ml/min. A 20 µl aliquot
of each sample was injected onto the column. The
25 mobile phase contained 14.2 g/liter monochloroacetate,
37 mg/liter EDTA, 300 mg/liter heptane sulfonic acid
and 3% methanol at a pH of 3.0.

The concentration of catecholamines and
30 selected metabolites was determined by comparing the
peak heights of serially diluted standards run with
each assay. The catecholamine detection limit of the
chromatographic system used was 15, 12 and 10 pg for
dopamine (DA), epinephrine (EPI), and norepinephrine
35 (NE), respectively.

WO 93/00439

PCT/US92/05390

-28-

Two wells from each group were sacrificed at 1, 4 and 8 weeks, and the remaining wells after 12 weeks in vitro, for morphological evaluation. Catecholamine release was expressed as either the average release/well in ng/15 min for statistical purposes or as per capsule (pg/capsule/15 min) obtained by dividing total catecholamine release by the number of microcapsules/well.

10 Mean and standard errors of the mean (S.E.M.) were calculated for each time point and group, with the exception of the size distribution of the cell-loaded microcapsules. The paired student t-test was used for statistical analysis.

15

One week following the encapsulation procedure, the potassium-evoked catecholamine release profile from four wells/group with each well containing approximately 300 microcapsules appeared very similar to that observed with the medium density chromaffin cell loaded microcapsules (FIG. 10). The quantities of NE/well measured over time decreased in a pattern similar to that which occurred in the medium density chromaffin microcapsules. At 4 weeks, a sharp decrease in the EPI output was seen, in contrast to the medium density chromaffin microcapsules (FIG. 11). By 8 weeks, EPI was detected in only 2 of the 4 wells stimulated with 56mM K⁺. A significant increase in the quantity of dopamine released was observed from 1 to 4 weeks in

WO 93/00439

PCT/US92/05390

-29-

the co-seeded capsules and remained at that elevated level up to 8 weeks in vitro (FIG. 11). Under static incubation conditions, treatment with 1 mM d-amphetamine sulphate induced a significant increase 5 in the output of NE and DA, as compared to basal levels after 8 weeks of maintenance in vitro.

EXAMPLE 4

Morphological Analysis

10

At selected times microcapsules were fixed in a 4% paraformaldehyde, 0.5% glutaraldehyde solution, rinsed in phosphate buffered saline (PBS), and dehydrated up to 95% ethanol. A 1:1 solution of 15 95% ethanol and the infiltration solution of glycol methacrylate (Historesin, Reichert-Jung for Cambridge Instruments) was next added to the specimens for 1 hour. Pure infiltration solution replaced the 1:1 mixture and remained for at least 2 hours. The 20 specimens were briefly rinsed with the embedding solution, transferred to flat molds, and embedded in glycol methacrylate. Sections 5 µm thick were sectioned (Reichert-Jung, Supercut microtome 2050), mounted on glass slides and stained for Nissl 25 substance with cresyl violet. After 4 and 8 weeks in vitro, the relationship and pattern of viability in the medium density chromaffin cell-loaded microcapsules was visualized by simultaneous staining with fluorescein diacetate (FDA) and propidium iodide 30 (PI). One ml suspensions from each time period with approximately 50 cell-loaded microspheres were exposed to working solutions as described by Jones et al. (J. Histochem. Cytochem. (1985) 33:77-79). An average of 10 microcapsules/time period were

WO 93/00439

PCT/US92/05390

-30-

evaluated first for PI (nonviable) and second with
FDA (viable) using a epifluorescent microscope (Zeiss
IM 35). For ultrastructural observations,
microcapsules were fixed in a 3% paraformaldehyde-
5 2% glutaraldehyde overnight, rinsed in 50 mM PBS, and
processed as described by Winn et al. (J. Biomed.
Mat. Res. (1989) 23:31-44). Ultrathin sections were
stained with Reynold's lead citrate and uranyl
acetate and analyzed with a Phillips 410 transmission
10 electron microscope.

In the co-seeded microcapsules, small
neurites were observed at the light microscopic level
extending from the chromaffin cells after 4 weeks in
15 vitro. In general, the chromaffin cells and
fibroblastic cell line remained isolated from one
another. Groups of fibroblasts were also observed
after the fourth week of maintenance in vitro. The
fibroblasts were observed to be in the vicinity of
20 Matrigel® within the capsule space. At the
ultrastructural level, neuritic extensions from the
chromaffin cells were identified, and the fibroblasts
continued to survive in the microcapsules after 12
weeks of maintenance in vitro. The fibroblasts were
25 multilayered, aligned along their long-axis, and were
identified as the fibroblast cell line on the basis
of their cytoplasmic contents.

The invention may be embodied in other
30 specific forms without departing from the spirit or
essential characteristics thereof. The present
embodiments are therefore to be considered in all

WO 93/00439

PCT/US92/05390

-31-

respects as illustrative and not restrictive, the scope of the invention being indicated by the appended claims rather than by the foregoing description, and all changes which come within the
5 meaning and range of equivalency of the claims are therefore intended to be embraced therein.

We claim:

WO 93/00439

PCT/US92/05390

-32-

Claims

1. A method of producing an active factor comprising the steps of:

5 providing at least one active factor-secreting cell obtained from a first source;
 providing at least one augmentary substance-secreting cell obtained from a second source different from said first
10 source;

 encapsulating said active factor-secreting cell and said augmentary substance-secreting cell within a semipermeable membrane, said membrane
15 allowing the diffusion of said active factor therethrough ; and
 culturing said encapsulated cells.

2. The method of claim 1 wherein said
20 encapsulating step further comprises disposing said cells within said semipermeable membrane, said membrane allowing the diffusion of solutes having a molecular weight of up to about 150,000 daltons therethrough.

WO 93/00439

PCT/US92/05390

-33-

3. The method of claim 1 wherein said encapsulating step further comprises disposing said cells within a semipermeable membrane composed of a material selected from the group consisting of

5 acrylic copolymers, polyvinylidene fluoride, polyurethane isocyanates, polyalginate, cellulose acetate, cellulose nitrate, polysulfone, polyvinyl alcohols, polyvinylchloride, polystyrene, polyurethane, polyamides, polymethylacrylate,

10 polysulfones, polyacrylates, polyacrylonitrile, polyethylene oxide, and derivatives and mixtures thereof.

4. The method of claim 1 wherein said

15 encapsulating step comprises disposing within said membrane a cell secreting an active factor selected from the group consisting of a neurotransmitter, neuromodulator, trophic factor, growth factor, cofactor, and hormone.

20

5. The method of claim 4 wherein said encapsulating step further comprises disposing within said membrane a cell secreting a neurotransmitter selected from the group consisting of dopamine,

25 norepinephrine, epinephrine, gamma aminobutyric acid, serotonin, glutamic acid, enkephalin, dynorphin, and acetylcholine.

WO 93/00439

PCT/US92/05390

-34-

6. The method of claim 4 wherein said encapsulating step further comprises disposing within said membrane a neurotransmitter-secreting cell, said neurotransmitter being dopamine, and said

5 neurotransmitter-secreting cell being isolated from a tissue or culture selected from the group consisting of adrenal medulla tissue, chromaffin cells, ventral mesencephalic embryonic tissue, and neuroblastoid tissue.

10

7. The method of claim 1 wherein said encapsulated step further comprises disposing within said membrane an active factor-producing chromaffin cell.

15

8. The method of claim 1 wherein said encapsulating step further comprises disposing within said membrane an active factor-producing cell that secretes one of the group consisting of a precursor, 20 analog, agonist, derivative, and fragment of an active factor each having active factor activity.

9. The method of claim 8 wherein said encapsulating step further comprises disposing within 25 said membrane a neurotransmitter-producing cell that secretes L-dopa.

10. The method of claim 8 wherein said encapsulating step further comprises disposing within 30 said membrane a neurotransmitter-producing cell that secretes bromocriptine.

WO 93/00439

PCT/US92/05390

-35-

11. The method of claim 1 wherein said encapsulating step comprises disposing within said membrane a cell that has been genetically engineered to produce an active factor or active analog or
5 active fragment thereof.

12. The method of claim 1 wherein said encapsulating step further comprises disposing within said membrane an augmentary substance which is a
10 growth factor.

13. The method of claim 1 wherein said encapsulating step further comprises disposing within said membrane a cell that secretes an augmentary
15 substance selected from the group consisting of epidermal growth factor (EGF), nerve growth factor (NGF), platelet-derived growth factor (PDGF), fibroblast growth factor (FGF), brain-derived neurotrophic factor (BDNF), and neutrophin-3 (NT-3).
20

14. The method of claim 13 wherein said encapsulating step further comprises disposing within said membrane a growth factor-producing cell that secretes NGF.
25

15. The method of claim 1 wherein said encapsulating step comprises disposing within said membrane a cell that has been genetically engineered to produce an augmentary substance.

WO 93/00439

PCT/US92/05390

-36-

16. The method of claim 1 wherein said encapsulating step further comprises disposing within said membrane an augmentary substance-producing cell that secretes one of the group consisting of a precursor, analog, agonist, derivative, and fragment of said augmentary substance, each having the biological activity of said augmentary substance.

17. The method of claim 1 wherein said encapsulating step further comprises disposing said cells within said membrane in a retrievable fashion, said membrane having a tubular shape with a first end and a second end, at least one of the ends having a cap element removably attached thereto to enable extraction of said cells therein.

18. The method of claim 1 wherein the step of culturing further comprises culturing said encapsulated cells in a physiologically compatible aqueous medium.

19. The method of claim 18 wherein the method further comprises extracting the active factor from said medium.

20. The method of claim 18 wherein the method further comprises accumulating the active factor in the encapsulated cells and then separating the encapsulated cells from the medium and lysing the capsules to extract the active factor.

WO 93/00439

PCT/US92/05390

-37-

21. A cell culture device for implantation within a subject for the delivery of an active factor to said subject, said device comprising:

5 a semipermeable membrane permitting the diffusion of an active factor therethrough, while excluding agents at the site of implantation which are detrimental to cells;

at least one active factor-secreting cell disposed within the membrane, said

10 active factor-secreting cell being obtained from a first source; and

at least one augmentary substance-producing cell disposed within said

15 membrane, said augmentary substance-secreting cell being obtained from a second source different from said first source, and secreting an augmentary substance that is different from said active factor and stimulates said active factor-producing cell

20 to secrete active factor.

22. The device of claim 21 wherein said semipermeable membrane is permeable to solutes having a molecular weight of up to about 150,000 daltons.

25

23. The device of claim 20 wherein said semipermeable membrane comprises a material selected from the group consisting of acrylic copolymers, polyvinylchloride, polyvinylidene fluoride,

30 polyurethane isocyanates, polyalginate, cellulose acetate, cellulose nitrate, polysulfone, polystyrene, polyurethane, polyvinyl alcohols, polyacrylonitrile, polyamides, polymethylmethacrylate, polyethylene oxide, and derivatives and mixtures thereof.

WO 93/00439

PCT/US92/05390

-38-

24. The device of claim 21 wherein said active factor-producing cell or said augmentary substance-producing cell is allospecific.

5 25. The device of claim 21 wherein said active factor-producing cell or said augmentary substance-producing cell is xenospecific.

26. The device of claim 21 wherein said
10 active factor-producing cell or said augmentary substance-producing cell has been genetically engineered to produce said active factor or said augmentary substance.

15 27. The device of claim 21 wherein said active factor-producing cell is a cell which produces an active factor selected from the group consisting of a neurotransmitter, neuromodulator, growth factor, trophic factor, cofactor, and hormone.

20

28. The device of claim 21 wherein said active factor is a neurotransmitter selected from the group consisting of dopamine, norepinephrine, epinephrine, acetylcholine, enkephalins, dynorphin,
25 substance P, gamma aminobutyric acid, glutamic acid, agonists, precursors, analogs, derivatives, and fragments thereof having neurotransmitter activity.

29. The device of claim 28 wherein said
30 neurotransmitter precursor is L-dopa.

30. The device of claim 28 wherein said neurotransmitter analog is bromocriptine.

WO 93/00439

PCT/US92/05390

-39-

31. The device of claim 21 wherein said active factor is dopamine, and said active factor-secreting cell is isolated from a tissue or culture selected from the group consisting of adrenal
5 medulla tissue, chromaffin cells, ventral mesencephalic embryonic tissue, neuroblastoid tissue, and a cell genetically engineered to produce dopamine.

32. The device of claim 21 wherein said
10 augmentary substance-producing cell produced an augmentary substance selected from the group consisting of nerve growth factor (NGF), epidermal growth factor (EGF), brain derived neutrophic factor (BDNF), neurotrophin-3 (NT-3), fibroblast growth
15 factor (FGF), platelet-derived growth factor (PDGF), and combinations thereof.

33. The device of claim 21 further comprising a retrievable, nonresorbable, and
20 biocompatible guide wire attached to said semipermeable membrane, so as to enable the removal of said device from said subject.

34. The device of claim 21 wherein said
25 semipermeable membrane is tubular, having at least one end with a cap element reversibly attached thereto.

35. The device of claim 21 wherein said
30 active factor-secreting cell and said augmentary substance-producing cell are disposed within said semipermeable membrane in a removable fashion, said membrane being tubular, having at least one end with a cap element reversibly attached thereto, so as to
35 enable extraction of said cells therein.

WO 93/00439

PCT/US92/05390

1/4




FIG. 1




FIG. 2




FIG. 3




FIG. 5




FIG. 6




FIG. 7

WO 93/00439

PCT/US92/05390

2/4




FIG. 4

WO 93/00439

PCT/US92/05390

3/4




FIG. 8




FIG. 9

WO 93/00439

PCT/US92/05390

4/4




FIG. 10




FIG. 11

INTERNATIONAL SEARCH REPORT

PCT/US 92/05390

International Application No

I. CLASSIFICATION OF SUBJECT MATTER (If several classification symbols apply, indicate all) ⁶		
According to International Patent Classification (IPC) or to both National Classification and IPC Int.Cl. 5 C12P1/00; A61K9/52; C12N5/00		
II. FIELDS SEARCHED		
Minimum Documentation Searched ⁷		
Classification System	Classification Symbols	
Int.Cl. 5	C12N ; A61K ; C12P	
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched ⁸		
III. DOCUMENTS CONSIDERED TO BE RELEVANT⁹		
Category ¹⁰	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³
X	WO,A,9 015 637 (BROWN UNIVERSITY RESEARCH FOUNDATION) 27 December 1990 see the whole document	1-35
A	WO,A,8 904 655 (BROWN UNIVERSITY RESEARCH FOUNDATION) 1 June 1989 see the whole document	1-35
A	GB,A,2 094 832 (DAMON CORPORATION). 22 September 1982 see the whole document	1-35
A	WO,A,9 015 877 (THE REGENTS OF THE UNIVERSITY OF MICHIGAN) 27 December 1990 see the whole document	1-20
-/-		
<p>* Special categories of cited documents : ¹⁰</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&" document member of the same patent family</p>		
IV. CERTIFICATION		
Date of the Actual Completion of the International Search 06 OCTOBER 1992		Date of Mailing of this International Search Report 21. 10. 92
International Searching Authority EUROPEAN PATENT OFFICE		Signature of Authorizing Officer HERNANDEZ Y BRA F.

PCT/US 92/05390

International Application No

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category *	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No.
A	<p>BIOLOGICAL ABSTRACTS vol. 91, no. 10 , May 1991, Philadelphia, PA, US; abstract no. 109891, AEBISCHER P. ET AL 'Long term cross-species brain transplantation of a polymer-encapsulated dopamine-secreting cell line' page AB-762 ; &Exp. neurol. vol 111(3):269-275 1991 see abstract</p> <p>-----</p>	1-35

**ANNEX TO THE INTERNATIONAL SEARCH REPORT
ON INTERNATIONAL PATENT APPLICATION NO. US 9205390
SA 61852**

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report.
The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information. 06/10/92

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A-9015637	27-12-90	AU-A- 5856590	08-01-91
		EP-A- 0478671	08-04-92
		US-A- 5106627	21-04-92

WO-A-8904655	01-06-89	US-A- 4892538	09-01-90
		AU-A- 2718488	14-06-89
		EP-A- 0388428	26-09-90
		JP-T- 3502534	13-06-91
		US-A- 5106627	21-04-92

GB-A-2094832	22-09-82	BE-A- 892478	01-07-82
		CA-A- 1172586	14-08-84
		CH-A- 662363	30-09-87
		DE-A, C 3209098	04-11-82
		FR-A, B 2501715	17-09-82
		JP-C- 1313474	28-04-86
		JP-A- 57202289	11-12-82
		JP-B- 60038111	30-08-85
		SE-B- 452335	23-11-87
		SE-A- 8201555	14-09-82
		US-A- 4495288	22-01-85

WO-A-9015877	27-12-90	EP-A- 0477290	01-04-92
